Insulin Glargine And Lixisenatide

Introduction Overview

Generic Name

insulin glargine and lixisenatide

Brand Name

Soliqua 100/33

Dosage Form

Autoinjector pen

Drug Class

Antidiabetic combinations

Pharmacokinetics

Absorption:

Soliqua 100/33 is administered subcutaneously and consists of insulin glargine, a long-acting basal insulin analog, and lixisenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Insulin glargine exhibits a slow and steady absorption profile, with detectable blood levels appearing within several hours post-injection and a flat, peakless profile lasting approximately 24 hours. Lixisenatide is rapidly absorbed following subcutaneous administration, reaching peak plasma concentration approximately 1 to 3 hours after injection. The combination allows lixisenatide's rapid onset to complement the prolonged action of insulin glargine, providing effective glycemic control throughout the day.

Distribution:

Insulin glargine distributes primarily within the vascular compartment due to its peptide nature, with limited volume of distribution similar to endogenous insulin. Lixisenatide binds to GLP-1 receptors and distributes in plasma with moderate volume reflecting its peptide nature and receptor binding characteristics. Due to their molecular sizes, both components do not readily cross the blood-brain barrier or distribute extensively into tissues. The steady release and receptor interaction ensure continuous pharmacodynamic effects on glucose metabolism.

Metabolism:

Insulin glargine is a modified insulin analog that, upon subcutaneous injection, forms microprecipitates, slowly releasing insulin glargine into the circulation where it is metabolized enzymatically to active metabolites by proteolytic degradation similar to endogenous insulin pathways in liver, muscle, and kidney. Lixisenatide undergoes proteolytic degradation primarily by dipeptidyl peptidase-4 (DPP-4) enzyme and general protein degradation pathways in plasma and tissues. The metabolic processing leads to inactive fragments excreted primarily via renal pathways.

Elimination:

Insulin glargine and its metabolites are cleared predominantly by the kidneys with lesser contributions from hepatic metabolism. The elimination half-life of insulin glargine is prolonged due to the slow absorption from the subcutaneous depot, contributing to its 20-24 hour duration of action. Lixisenatide is cleared mainly via renal excretion of peptide fragments after proteolytic metabolism, with an elimination half-life of approximately 3 hours, allowing it to exert pharmacologic effects predominantly in the postprandial period following injection. Renal impairment can reduce lixisenatide clearance, necessitating caution or dose adjustments. Overall, the combination in Soliqua provides steady basal insulin coverage with enhanced postprandial glucose control.

Dosage Forms

Available Dosage Forms:
Soliqua 100/33 is available as a prefilled pen injector (autoinjector) containing 300 units of insulin glargine and 99 micrograms of lixisenatide per 3 mL cartridge. The concentration corresponds to 100 units/mL insulin glargine and 33 mcg/mL lixisenatide. The pen device is designed for subcutaneous injection with adjustable dosing from 15 to 60 units.

Dosages for Adults and Adolescents:
The recommended initial dose depends on prior treatment. For patients naive to basal insulin or GLP-1 receptor agonists, or those on GLP-1 receptor agonists or less than 30 units/day basal insulin, the initial dose is 15 units subcutaneously once daily. For patients already receiving 30 to 60 units basal insulin, with or without GLP-1 receptor agonist, initial dosing starts at 30 units once daily. Dose is titrated weekly in increments of 2 to 4 units based on blood glucose monitoring and glycemic goals until the desired fasting plasma glucose is achieved. Maintenance dosing ranges from 15 to 60 units daily, with a maximum recommended dose of 60 units insulin glargine/20 mcg lixisenatide daily.

Specific Patient Populations:
Soliqua is indicated for adults with type 2 diabetes mellitus and is not recommended for type 1 diabetes or diabetic ketoacidosis. Dose titration should consider renal or hepatic impairment, as lixisenatide clearance is affected by renal function. The combination should be avoided or used cautiously in patients with history of pancreatitis. It is not established in pediatric populations. Use during pregnancy or breastfeeding requires individualized risk-benefit assessment and close monitoring. The injection site should be rotated to avoid lipodystrophy or local skin reactions. Patients with heart failure or hypokalemia history warrant special precautions.

Clinical guidelines emphasize usage within one hour prior to the first meal to optimize efficacy. The pen device should be stored refrigerated before opening, and at room temperature after first use for up to 28 days. Needles are sold separately and should be compatible with the device.

Mechanism Of Action

Soliqua 100/33 combines two distinct but complementary agents: insulin glargine, a long-acting basal insulin analog, and lixisenatide, a GLP-1 receptor agonist, working synergistically to improve glycemic control in type 2 diabetes.

Insulin glargine functions by mimicking endogenous insulin secretion, providing a steady, peakless basal insulin level that facilitates glucose uptake by peripheral tissues, primarily muscle and adipose tissue, and suppresses hepatic glucose production. Its structural modifications enable the formation of microprecipitates at subcutaneous injection sites, resulting in slow and consistent absorption over 24 hours. Insulin glargine binds to insulin receptors, activating intracellular signaling pathways such as the PI3K-Akt cascade, leading to increased translocation of GLUT4 glucose transporters to the cell surface and increased glucose utilization.

Lixisenatide is a glucagon-like peptide-1 receptor agonist that enhances glucose-dependent insulin secretion from pancreatic beta cells. It prolongs gastric emptying time, reducing postprandial glucose excursions by slowing nutrient absorption, and suppresses inappropriate glucagon secretion from alpha cells. By activating GLP-1 receptors, lixisenatide also promotes satiety and may contribute to weight reduction. Its glucose-dependent mechanism reduces the risk of hypoglycemia.

The combined action enables Soliqua to address multiple pathophysiologic defects of type 2 diabetes: impaired basal insulin secretion, defective postprandial insulin response, and excess glucagon secretion. Clinical studies show this combination improves fasting and postprandial glycemic control more effectively than either agent alone, with the potential benefit of weight neutrality or modest weight loss compared to basal insulin alone. This dual mechanism addresses both fasting and mealtime glucose levels, offering a more physiological approach to glucose regulation.

Compared to other combination therapies such as Xultophy (insulin degludec and liraglutide), Soliqua provides differing pharmacokinetics and receptor engagement based on its specific components, offering tailored options according to patient response and tolerance.

Pharmacological Actions

Basal insulin activity via insulin glargine providing prolonged glucose-lowering effects over 24 hours.
Glucose-dependent stimulation of insulin secretion by lixisenatide through GLP-1 receptor activation.
Suppression of postprandial glucagon secretion, reducing hepatic glucose output.
Delay of gastric emptying by lixisenatide, modulating postprandial glucose absorption.
Reduction of appetite and potential for weight modulation via central GLP-1 receptor effects.
Improvement of peripheral glucose uptake through activation of insulin signaling pathways.
Reduction in both fasting and postprandial hyperglycemia leading to improved overall glycemic control.
Complementary mechanisms reduce risk of hypoglycemia compared to insulin monotherapy due to glucose-dependent insulin release.
Modulation of pancreatic beta-cell function, potentially preserving endogenous insulin secretion.
Reduction of HbA1c levels as demonstrated in clinical trials involving type 2 diabetes patients.

Therapeutic Or Clinical Uses

Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Treatment of patients inadequately controlled on basal insulin or GLP-1 receptor agonist monotherapy.
Improvement of both fasting and postprandial blood glucose levels.
Alternative to basal insulin or GLP-1 receptor agonist monotherapy to enhance metabolic control.
Used in patients requiring combination therapy without needing prandial (mealtime) insulin.
Option for patients seeking once-daily injection regimen for convenience and adherence.
May benefit patients with obesity or overweight due to potential weight neutrality or mild weight loss effects.
Not indicated for type 1 diabetes mellitus or diabetic ketoacidosis management.
Utilized in patients with stable renal function; caution advised in moderate to severe renal impairment.
May be used to reduce HbA1c when previous therapies are insufficient.

Side Or Adverse Effects

Hypoglycemia, particularly if combined with other glucose-lowering agents or improper dosing.
Nausea, often transient and more common during initial therapy due to lixisenatide component.
Diarrhea as a gastrointestinal side effect related to GLP-1 receptor agonist activity.
Headache, reported in clinical settings but generally mild.
Cold-like symptoms including nasal congestion, sneezing, and sore throat.
Pancreatitis manifesting as severe upper abdominal pain radiating to the back, requiring immediate medical attention.
Hypokalemia (low potassium levels), which can cause muscle cramps, arrhythmias, and weakness.
Injection site reactions such as redness, swelling, or irritation.
Weight neutrality or slight weight loss compared to other insulin therapies.
Rare allergic reactions including urticaria, pruritus, rash, or anaphylaxis.
Fluid retention and potential worsening of heart failure symptoms in susceptible patients.
Potential for gastrointestinal discomfort including vomiting or constipation.
Risk of serious hypoglycemia in overdose or inappropriate combination with other antidiabetic agents.
Possible dehydration from persistent vomiting or diarrhea leading to renal impairment.

Precautions

Do not use Soliqua in patients with type 1 diabetes or diabetic ketoacidosis.
Avoid concomitant use with short-acting mealtime insulin or other GLP-1 receptor agonists to prevent overdose.
Monitor for signs of pancreatitis, particularly in patients with history of pancreatic disease.
Exercise caution in patients with history of heart failure due to fluid retention risk.
Monitor serum potassium levels during treatment, especially in patients using diuretics or at risk for hypokalemia.
Adjust dose cautiously in patients with renal or hepatic impairment due to altered drug clearance.
Avoid injection into areas with skin lesions, scars, or lipodystrophy to ensure effective absorption.
Educate patients about hypoglycemia recognition and treatment, particularly when combined with other glucose-lowering drugs.
Use during pregnancy only if clearly needed; strict glycemic control is essential during gestation.
Do not share injection pens or needles to prevent transmission of infections.
Store unopened pens refrigerated; do not freeze. Pens in use can be stored at room temperature up to 28 days.
Advise patients to drink plenty of fluids to prevent dehydration during episodes of vomiting or diarrhea.
Dose titration should be individualized based on blood glucose monitoring and metabolic needs.
Patients should avoid alcohol consumption which may exacerbate hypoglycemia risk.

Warnings

Stop using Soliqua and seek immediate medical attention if severe upper abdominal pain with nausea and vomiting occurs indicating possible pancreatitis.
Never share injection pens, cartridges, or syringes with others to avoid risk of infection transmission.
Hypoglycemia can be life-threatening; patients must be instructed on prevention and management.
Use caution in patients with a history of severe allergic reactions to insulin or lixisenatide.
May cause hypokalemia which can lead to cardiac arrhythmias if untreated.
Risk of dehydration, especially during prolonged vomiting or diarrhea, which may precipitate kidney failure.
Concomitant use with certain oral medications may affect absorption or efficacy.
Adjust dosing in response to changes in physical activity, diet, illness, or other medications to avoid hypoglycemia or hyperglycemia.
Not for use in patients requiring rapid-acting mealtime insulin.
Patients should be monitored for signs of heart failure exacerbation such as sudden weight gain or edema.

Contraindication

Known hypersensitivity to insulin glargine, lixisenatide, or any component of the formulation.
Patients with type 1 diabetes mellitus.
During episodes of diabetic ketoacidosis.
Concurrent use with short-acting mealtime insulin or other GLP-1 receptor agonists such as exenatide, liraglutide, dulaglutide.
History of severe allergic or anaphylactic reactions to insulin products or GLP-1 receptor agonists.
Severe renal impairment or end-stage renal disease due to lixisenatide clearance concerns (relative contraindication).
Patients with gastroparesis or severe gastrointestinal motility disorders.
Pregnant or breastfeeding women without healthcare provider guidance and risk assessment.
Patients with a history of pancreatitis should avoid or closely monitored on therapy.
Unstable cardiac conditions, especially heart failure with fluid retention.

Drug Interactions

Concomitant use with other antidiabetic agents such as sulfonylureas or insulin increases risk of hypoglycemia.
Lixisenatide may delay absorption of oral medications including antibiotics, acetaminophen, and oral contraceptives; dose these at least 1 hour before Soliqua injection.
Interactions with thiazolidinediones (pioglitazone, rosiglitazone) may increase risk of heart failure when combined with insulin.
Drugs that affect potassium levels such as diuretics, corticosteroids, or beta-agonists may exacerbate hypokalemia risk.
Agents that blunt hypoglycemia awareness (e.g., beta-blockers) can mask symptoms when used concomitantly.
Medications affecting gastrointestinal motility may alter lixisenatide absorption and efficacy.
Alcohol can potentiate hypoglycemic effects and should be avoided during therapy.
Drugs requiring precise dosing in relation to meals (e.g., warfarin) may be affected due to lixisenatide's effect on gastric emptying.
Avoid concurrent use with other GLP-1 receptor agonists to prevent additive adverse effects.
Potential interactions with immunosuppressants or corticosteroids that affect blood glucose levels.
Herbal supplements with hypoglycemic potential (e.g., ginkgo, ginseng) should be used cautiously.
Concomitant use of agents that prolong QT interval should be monitored carefully due to electrolyte disturbances.
Adjustments may be necessary for patients on multiple medications affecting glucose metabolism.
Always inform healthcare providers of all prescription, over-the-counter, and herbal products being used.

Preparations Of The Drug

Soliqua 100/33 comes as a prefilled reusable autoinjector pen containing 3 mL of solution (100 units/mL insulin glargine and 33 mcg/mL lixisenatide).
Available strength is insulin glargine 100 units per mL combined with lixisenatide 33 mcg per mL.
Each pen contains a total of 300 units insulin glargine and 99 mcg lixisenatide.
Designed for subcutaneous injection with dosing increments adjustable via dial, from 15 to 60 units daily.
Pens are intended for single-patient use and should never be shared.
Needle devices are not included and must be purchased separately; only compatible pen needles should be used.
Unopened pens require refrigeration between 2°C and 8°C (36°F to 46°F) and protection from light.
Once in use, pens can be stored at room temperature (up to 30°C or 86°F) for a maximum of 28 days.
The solution is clear and colorless; do not use if cloudy, discolored, or containing particles.
Dispose of used needles safely in approved sharps containers to prevent injury and contamination.
Packaging includes detailed instructions for use, storage, and disposal to ensure patient safety and efficacy.
Pen design includes dose lockout above 60 units to prevent overdose.
Preparation features combination therapy in a single device for improved adherence.
FDA-approved by Sanofi-Aventis U.S. LLC, with ongoing pharmacovigilance for safety monitoring.